AsianFin -- Sciwind Biosciences is in discussions with a U.S. company over a potential licensing deal for its experimental weight-loss drug, Reuters reported, citing the Chinese biotech firm’s CEO.

The drug, ecnoglutide, helped overweight patients shed 10% to 15% of their body weight in a late-stage trial—results comparable to Novo Nordisk’s blockbuster obesity drug Wegovy. The findings were published in The Lancet Diabetes & Endocrinology in June.